Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 3/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580519 | 0.86 | SMN1; SMN2 (0.47) | NAMPTSMN1; SMN2LMNAHPGDHTT | |
| SCHEMBL1242307 | 0.82 | KCNA5 (0.48) | NAMPTVNN1KCNA5SGMS2MGLL | |
| SCHEMBL1242132 | 0.82 | KCNA5 (0.46) | NAMPTSMN1; SMN2LMNAVNN1KCNA5 | |
| SCHEMBL1240759 | 0.78 | KCNA5 (0.46) | LMNAHPGDKCNA5ALDH1A1 | |
| SCHEMBL1376729 | 0.78 | KCNA5 (0.46) | NAMPTVNN1KCNA5SGMS2MGLL | |
| SCHEMBL1242332 | 0.78 | CYP19A1 (0.48) | HPGDVNN1KCNA5SGMS2ALDH1A1 | |
| SCHEMBL1242185 | 0.78 | GRM4 (0.54) | HTTVNN1KCNA5SGMS2ALDH1A1 | |
| SCHEMBL1240885 | 0.77 | C3AR1 (0.46) | LMNAVNN1KCNA5SGMS2ALDH1A1 | |
| SCHEMBL1242304 | 0.76 | KCNA5 (0.47) | NAMPTVNN1KCNA5SGMS2MGLL | |
| SCHEMBL1240492 | 0.76 | DGAT2 (0.51) | NAMPTSMN1; SMN2LMNAHTTVNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781635-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | NAMPT 1389/4885SMN1; SMN2 4477/4885LMNA 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.